PMID- 36990372
OWN - NLM
STAT- MEDLINE
DCOM- 20230510
LR  - 20230518
IS  - 1873-7528 (Electronic)
IS  - 0149-7634 (Linking)
VI  - 149
DP  - 2023 Jun
TI  - Trust the gut: Outcomes of gut microbiota transplant in metabolic and cognitive 
      disorders.
PG  - 105143
LID - S0149-7634(23)00112-4 [pii]
LID - 10.1016/j.neubiorev.2023.105143 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a main public health concern, with increasing 
      prevalence and growingly premature onset in children, in spite of emerging and 
      successful therapeutic options. T2DM promotes brain aging, and younger age at 
      onset is associated with a higher risk of subsequent dementia. Preventive 
      strategies should address predisposing conditions, like obesity and metabolic 
      syndrome, and be started from very early and even prenatal life. Gut microbiota 
      is an emerging target in obesity, diabetes and neurocognitive diseases, which 
      could be safely modulated since pregnancy and infancy. Many correlative studies 
      have supported its involvement in disease pathophysiology. Faecal material 
      transplantation (FMT) studies have been conducted in clinical and preclinical 
      settings to deliver cause-effect proof and mechanistic insights. This review 
      provides a comprehensive overview of studies in which FMT was used to cure or 
      cause obesity, metabolic syndrome, T2DM, cognitive decline and Alzheimer's 
      disease, including the evidence available in early life. Findings were analysed 
      to dissect consolidated from controversial results, highlighting gaps and 
      possible future directions.
CI  - Copyright (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Guzzardi, Maria Angela
AU  - Guzzardi MA
AD  - Institute of Clinical Physiology (IFC), the National Research Council (CNR), via 
      Moruzzi 1, 56124 Pisa, Italy. Electronic address: mariaangela.guzzardi@cnr.it.
FAU - La Rosa, Federica
AU  - La Rosa F
AD  - Institute of Clinical Physiology (IFC), the National Research Council (CNR), via 
      Moruzzi 1, 56124 Pisa, Italy. Electronic address: larosa.fed@gmail.com.
FAU - Iozzo, Patricia
AU  - Iozzo P
AD  - Institute of Clinical Physiology (IFC), the National Research Council (CNR), via 
      Moruzzi 1, 56124 Pisa, Italy. Electronic address: patricia.iozzo@cnr.it.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230327
PL  - United States
TA  - Neurosci Biobehav Rev
JT  - Neuroscience and biobehavioral reviews
JID - 7806090
SB  - IM
MH  - Child
MH  - Humans
MH  - *Metabolic Syndrome/therapy
MH  - *Gastrointestinal Microbiome/physiology
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - Trust
MH  - Obesity/therapy
MH  - *Cognitive Dysfunction/therapy
OTO - NOTNLM
OT  - Alzheimer's
OT  - Cognitive decline
OT  - Early life
OT  - Fecal material transplantation
OT  - In vivo imaging
OT  - Obesity
OT  - Type 2 diabetes
COIS- Declaration of Competing Interest The authors declare that they have no competing 
      interests.
EDAT- 2023/03/30 06:00
MHDA- 2023/05/10 06:42
CRDT- 2023/03/29 19:35
PHST- 2023/01/31 00:00 [received]
PHST- 2023/03/21 00:00 [revised]
PHST- 2023/03/24 00:00 [accepted]
PHST- 2023/05/10 06:42 [medline]
PHST- 2023/03/30 06:00 [pubmed]
PHST- 2023/03/29 19:35 [entrez]
AID - S0149-7634(23)00112-4 [pii]
AID - 10.1016/j.neubiorev.2023.105143 [doi]
PST - ppublish
SO  - Neurosci Biobehav Rev. 2023 Jun;149:105143. doi: 10.1016/j.neubiorev.2023.105143. 
      Epub 2023 Mar 27.